Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was downgraded by Vetr from a "strong-buy" rating to a "buy" rating in a report released on Monday, September 4th. The company now has an average rating of "Hold" and a consensus target price of $102.80. The firm has price to earnings ratio stands at 153.76, it indicates the expected price of a share based on its earnings.
Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals has an average rating of "Buy" and a consensus target price of $162.88.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ended its day at $158.83 with the rising stream of -0.36% and its total traded volume was 1.04 million shares less than the average volume. Cowen and Company reaffirmed a "market perform" rating and set a $105.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, July 6th. BMO Capital Markets maintained the stock with "Buy" rating in Tuesday, July 18 report. Six investment analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company's stock. J.P. Morgan maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, July 19.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, January 25th. 232.42 million shares or 0.81% less from 234.32 million shares in 2016Q3 were reported. The firm has a 50-day moving average of $155.29 and a 200 day moving average of $125.51. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since September 12, 2016 and is uptrending. Strs Ohio reported 0.11% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The pharmaceutical company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company had revenue of $544.10 million for the quarter, compared to analysts' expectations of $489.95 million. During the same period in the previous year, the firm posted $0.24 EPS. VRTX generated revenue of $648.98 Million in the same quarter, one year ago. First Manhattan Co. lifted its position in shares of Vertex Pharmaceuticals by 1.3% during the first quarter. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright legislation. The PEG ratio is used to determine a stock's value while taking the company's earnings growth into account, and is considered to provide a more complete picture than the P/E ratio.
In other Vertex Pharmaceuticals news, CMO Jeffrey Chodakewitz sold 5,157 shares of the stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $132.87, for a total transaction of $685,210.59. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 28,320 shares were sold by Arbuckle Stuart A, worth $3.38M on Friday, April 28. Regal Investment Advisors Llc sold 3,810 shares as Disney Walt Co (DIS)'s stock declined 2.31%. Following the transaction, the senior vice president now directly owns 22,648 shares in the company, valued at approximately $3,020,337.28. The disclosure for this sale can be found here.
A number of large investors have recently added to or reduced their stakes in the stock. Achmea Investment Management B.V. boosted its holdings in Vertex Pharmaceuticals by 68.0% in the second quarter. (NYSE:HPQ) reached at $19.32 price level during last trade its distance from 20 days simple moving average is 1.33%, and its distance from 50 days simple moving average is 2.84% while it has a distance of 11.09% from the 200 days simple moving average. LLC boosted its holdings in Vertex Pharmaceuticals by 88.1% in the second quarter. MARSHALL WACE ASIA Ltd purchased a new stake in Vertex Pharmaceuticals during the 1st quarter valued at $46,278,000. Jennison Associates LLC raised its holdings in Vertex Pharmaceuticals by 253.8% during the 2nd quarter.
Switzerland-based Credit Suisse Ag has invested 0.05% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications.